Skip to Main Content

Paper Details

Saracatinib, a Selective Src Kinase Inhibitor, Blocks Fibrotic Responses in Preclinical Models of Pulmonary Fibrosis.
Am J Respir Crit Care Med
25
2022
Ad-TGF-?, IPF, IPF disease, Idiopathic Pulmonary Fibrosis, NHLFs, Pulmonary Fibrosis, Saracatinib, Src, Src Kinase, Src kinase, TGF-?, WNT, bleomycin, fibrosis, gene sets, human, lung fibrosis, mice, nintedanib, normal human lung fibroblasts, patients, pirfenidone, pulmonary fibrosis, recombinant adenovirus transforming growth factor-beta, saracatinib
Author NameAffiliation
Ben ReadheadInstitute for Next Generation Healthcare
Ben ReadheadASU-Banner Neurodegenerative Disease Research Center, Arizona State University
Charles S Dela CruzYale University School of Medicine
Joel T DudleyInstitute for Next Generation Healthcare
Joel T DudleyInstitute for Next Generation Healthcare
  • 1 - 5

Datasets

Release 1.2